Mirum Pharmaceuticals, Inc. (MIRM) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19
	8-K	10-K	10-K	10-K
Revenues:
License revenue	2.0
Research and development	106.8
Product sales, net	75.1
Total revenues [+]	77.1	19.1	0.0	0.0
Licensing	2.0
Royalties	106.8
Products	75.1
Revenue growth	302.7%
Cost of goods sold	0.0	0.0	0.0	0.0
Gross profit	77.1	19.1	0.0	0.0
Gross margin	100.0%	100.0%
Selling, general and administrative [+]	89.1	192.6	104.3	11.8
General and administrative				11.8
Research and development		131.4	81.6	43.0
Other operating expenses	119.2	-131.4	-81.6
EBITDA [+]		-172.8	-104.0	-54.6
EBITDA growth	-24.1%	66.2%	90.4%
EBITDA margin	-170.3%	-903.0%
Depreciation and amortization		0.6	0.3	0.1
EBIT [+]	-131.2	-173.4	-104.3	-54.7
EBIT growth	-24.3%	66.3%	90.5%
EBIT margin	-170.3%	-906.1%
Interest expense, net [+]	16.0	-0.4	-1.6	-2.2
Interest expense	16.0
Interest income		0.4	1.6	2.2
Other income (expense), net [+]	5.1	89.1	-0.5	0.0
Unrealized gain/loss on derivatives	0.9
Other				0.0
Pre-tax income	-142.1	-84.0	-103.3	-52.5
Income taxes	-6.4	0.0	0.0	0.0
Tax rate	4.5%
Net income	-135.7	-84.0	-103.3	-52.6
Net margin	-176.0%	-438.9%

Basic EPS [+]	($4.01)	($2.77)	($4.09)	($4.58)
Growth	44.7%	-32.3%	-10.6%
Diluted EPS [+]	($3.99)	($2.77)	($4.09)	($4.58)
Growth	44.1%	-32.3%	-10.6%

Shares outstanding (basic) [+]	33.8	30.3	25.3	11.5
Growth	11.6%	20.1%	119.8%
Shares outstanding (diluted) [+]	34.0	30.3	25.3	11.5
Growth	12.1%	20.1%	119.8%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.